Information Provided By:
Fly News Breaks for March 12, 2018
CHRS, AMGN
Mar 12, 2018 | 08:21 EDT
Morgan Stanley analyst Matthew Harrison noted that on Friday the USPTO's Patent Trial and Appeal Board denied the institution of two IPRs filed by Coherus Biosciences (CHRS) against Enbrel patients 8,063,182 and 8,163,522, which he said removes one near-term overhang on Amgen (AMGN) shares. Harrison noted that he has always viewed the IPRs as a greater risk to Enbrel than a District Court case being brought by Novartis' (NVS) Sandoz division, which is set to begin its trial on April 17, as he has always seen a potential settlement with Sandoz as a reasonable possibility. The analyst keeps his Overweight rating and $196 price target on Amgen shares.
News For AMGN;CHRS From the Last 2 Days
There are no results for your query AMGN;CHRS